New, but not improved? Incorporating comparative-effectiveness information into FDA labeling.
Stafford
Randall S
RS
Stanford Prevention Research Center, Stanford University, Palo Alto, California, USA.
Wagner
Todd H
TH
Lavori
Philip W
PW
D003362:Cost-Benefit Analysis; D004348:Drug Labeling / Q000331:legislation & jurisprudence* / Q000639:trends; D033161:Government Regulation; D006302:Health Services Research; D006801:Humans; D013810:Therapeutic Equivalency; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration